In Brief: revised NDI draft expected in 2013, MusclePharm invests, Sundial label and GMP warnings, AHPA publishes organic guidance
This article was originally published in The Tan Sheet
Executive Summary
CFSAN plans revised NDI draft in 2013; MusclePharm invests in BioZone delivery tech; Indiana kicks off anti-smurfing campaign; Sundial fails basic labeling, GMP compliance; AHPA advises supplement firms on organic rules; Naturex commits to sustainability; Targeted Medical Pharma expands into supplements.
You may also be interested in...
Energy Drinks Swayed By Liquid Supplement Draft Guidance After All
Monster Energy products will transition from supplement to conventional food labeling, in a sign that industry may be adapting to FDA’s draft guidance on liquid supplements that stirred controversy upon its publication in 2009.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.